Want to see USPH full AI Analyst Report?
USPH Stock Chart & Stats
$77.32
$1.61(2.21%)
At close: 4:00 PM EDT
$77.32
$1.61(2.21%)
Day’s Range― - ―
52-Week Range$58.19 - $93.50
Previous Close$74.58
Volume178.65K
Average Volume (3M)180.44K
Market Cap
$1.28B
Enterprise Value$1.71B
Total Cash (Recent Filing)$24.89M
Total Debt (Recent Filing)$385.79M
Price to Earnings (P/E)504.2
Beta1.06
Next Earnings
Nov 10, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend Yield2.14%
Share Statistics
EPS (TTM)0.17
Shares Outstanding14,922,698
10 Day Avg. Volume186,626
30 Day Avg. Volume180,440
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)2.49
Price to Sales (P/S)1.52
P/FCF Ratio19.43
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit11.47
Enterprise Value/Ebitda17.03
Forecast
1Y Price Target
$93.67Price Target Upside21.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.75
Revenue Forecast (FY)$847.90M
Bulls Say, Bears Say
Bulls Say
Volume And Rate GrowthStrong patient-volume growth combined with higher revenue per visit indicates improving utilization and reimbursement across the core therapy business. Sustained clinic productivity can support revenue expansion and operating leverage, strengthening the platform’s earnings potential over the next several quarters.
Hospital Affiliation ExpansionThe hospital-affiliation rollout creates a visible expansion path beyond organic clinic growth. Initial revenue contribution and the remaining integration pipeline provide opportunities for higher scale, broader referral relationships, and additional earnings growth as implementation costs moderate and clinics become fully onboarded.
Acquisition-Led ScaleOngoing acquisitions add clinics, patient visits, and revenue to an established operating platform. This strategy can compound scale in a fragmented outpatient rehabilitation market, while management and billing capabilities may allow acquired practices to contribute more efficiently as integration progresses.
Bears Say
Margin PressureThe decline in physical therapy gross margin shows that revenue growth is not currently translating proportionally into profit. Elevated employee healthcare costs and front-loaded implementation spending could remain a drag on earnings until staffing normalizes and hospital affiliations reach a more mature operating stage.
Higher BorrowingsHigher borrowings and lower cash reduce financial flexibility relative to the prior year, even though the company retains revolver availability. Greater debt exposure can increase interest burden and constrain capital allocation while USPH funds acquisitions, integrations, and continued clinic expansion.
Compressed Earnings PowerRecent trailing results indicate that the company’s underlying earnings power remains weak despite the stronger latest quarter. Lower revenue and thin profitability provide less cushion against operating cost increases, and subdued returns may limit internally generated capital for sustained expansion.
US Physical Therapy News
USPH FAQ
What was U.s. Physical Therapy’s price range in the past 12 months?
U.s. Physical Therapy lowest stock price was $58.19 and its highest was $93.50 in the past 12 months.
What is U.s. Physical Therapy’s market cap?
U.s. Physical Therapy’s market cap is $1.28B.
When is U.s. Physical Therapy’s upcoming earnings report date?
U.s. Physical Therapy’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were U.s. Physical Therapy’s earnings last quarter?
U.s. Physical Therapy released its earnings results on Aug 05, 2026. The company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.814 by -$0.064.
Is U.s. Physical Therapy overvalued?
According to Wall Street analysts U.s. Physical Therapy’s price is currently Undervalued.
Does U.s. Physical Therapy pay dividends?
U.s. Physical Therapy pays a Quarterly dividend of $0.46 which represents an annual dividend yield of 2.14%. See more information on U.s. Physical Therapy dividends here
What is U.s. Physical Therapy’s EPS estimate?
U.s. Physical Therapy’s EPS estimate is 0.76.
How many shares outstanding does U.s. Physical Therapy have?
U.s. Physical Therapy has 14,922,698 shares outstanding.
What happened to U.s. Physical Therapy’s price movement after its last earnings report?
U.s. Physical Therapy reported an EPS of $0.75 in its last earnings report, missing expectations of $0.814. Following the earnings report the stock price went down -1.608%.
Which hedge fund is a major shareholder of U.s. Physical Therapy?
Currently, no hedge funds are holding shares in USPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
US Physical Therapy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.67 (21.14% Upside)
$93.67 (21.14% Upside)
Blogger Sentiment
Neutral
USPH Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 87.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.76%
12-Months-Change
Fundamentals
Return on Equity
-1.27%
Trailing 12-Months
Asset Growth
5.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
U.s. Physical Therapy
U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal conditions, recovery from sports-related trauma, proactive health measures, assistance for workers recovering from injuries, and care for neurological conditions. The company's business is divided into two primary divisions: Physical Therapy Operations and Industrial Injury Prevention Services. Within its industrial segment, it provides specialized services like on-site injury avoidance and recovery programs, strategies for enhancing physical performance, pre-employment screening tests, assessments of an individual's work capacity, and workplace ergonomic reviews. These offerings are delivered by licensed physical therapists and expert certified athletic trainers to a diverse clientele, including Fortune 500 corporations, insurance providers, and their associated contractors. By the end of 2021, specifically December 31st, the company had established 591 operational clinics across 39 states, in addition to overseeing 35 other physical therapy sites. Established in 1990, the company maintains its headquarters in Houston, Texas.
USPH Company Deck
USPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrays strong operational momentum — solid revenue growth, record visit volumes, improving revenue per visit, active M&A and an expanding hospital-affiliation pipeline that management expects will materially lift results in late 2023 and 2027. Near-term profitability was pressured by elevated employee self-insured medical costs, front-loaded hiring for hospital rollouts and integration costs, leading to margin compression, lower net income and EPS. Management reaffirmed full-year adjusted EBITDA guidance and highlighted meaningful upside from ongoing hospital affiliations and rate increases, indicating confidence in future performance.View all USPH earnings summariesUSPH Stock 12 Month Forecast
Average Price Target
$93.67
▲(21.14% Upside)
Technical Analysis
Encompass Health
―
National Healthcare
―
The Ensign Group
―
Pennant Group
―
Concentra Group Holdings Parent, Inc.
―
Ownership Overview
2.37% Insiders
29.63% Mutual Funds
12.43% Other Institutional Investors
27.81% Public Companies and
Individual Investors